SCHEMBL865136

SCHEMBL865136

O=C(ON1C(=O)CCC1=O)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.40

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 5/20 0.40
PARL Q9H300 2/20 0.34
KMT2A Q03164 1/20 0.32
ATM Q13315 1/20 0.32
GLA P06280 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA9 Q16790 1/20 0.31
ALOX12 P18054 1/20 0.31
FAAH O00519 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL118685 0.90 PARL (0.41) MGLLPARLKMT2AATMCA12
SCHEMBL13423603 0.89 MGLL (0.36) MGLL
SCHEMBL10889616 0.85 GLA (0.39) MGLLPARLKMT2AATMGLA
SCHEMBL28377582 0.85 MGLL (0.36) MGLLPARL
SCHEMBL1580294 0.84 MGLL (0.38) MGLLPARL
SCHEMBL28964134 0.84 MGLL (0.36) MGLLPARLKMT2AATMCA12
SCHEMBL17447 0.83 MGLL (0.37) MGLLPARLGLACA12CA1
SCHEMBL11596423 0.83 ALDH1A1 (0.37) MGLLKMT2AATM
Ethylene Glycol SCHEMBL29130624 0.82 PARL (0.36) MGLLPARLKMT2AATMALOX12
SCHEMBL73278 0.82 KMT2A (0.47) MGLLKMT2AATMGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 256 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110204576-B Preparation method of lithium difluorobis (oxalato) phosphate solution 东莞东阳光科研发有限公司 2021-09-10 CN claimed
US-20200388880-A1 SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS ENEVATE CORPORATION 2020-12-10 US claimed
CN-109072482-A MULTIVALENT GLYCAN MICROARRAY PLATFORM Z生物科技有限公司 2018-12-21 CN claimed
US-20100022415-A1 ACTIVE CARRIER, ITS PRODUCTION AND ITS USE AVICOR KET. (HU) 2010-01-28 US claimed
CN-101553731-A Active carrier, its production and its use AVICOR KFT (HU) 2009-10-07 CN claimed
EP-2080026-A1 ACTIVE CARRIER, ITS PRODUCTION AND ITS USE Avicor Kft. (HU) 2009-07-22 EP claimed
WO-2008023208-A1 ACTIVE CARRIER, ITS PRODUCTION AND ITS USE AVICOR KFT. (HU) 2008-02-28 WO claimed
JP-2006517995-A 2006-08-03 JP claimed
EP-1597299-A2 CARBONATE ESTERS OF POLYETHYLENE GLYCOL ACTIVATED BY MEANS OF OXALATE ESTERS Pharmacia Corporation (US) 2005-11-23 EP claimed
EP-1131281-B1 DERIVATISATION OF SUPPORT SURFACES DEUTSCHES KREBSFORSCH (DE) 2005-07-27 EP claimed
US-6905724-B1 Derivatization of support surfaces DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) 2005-06-14 US claimed
US-20050059068-A1 Compositions and methods using dendrimer-treated microassays STRATAGENE CALIFORNIA 2005-03-17 US claimed
WO-2004074345-A2 CARBONATE ESTERS OF POLYETHYLENE GLYCOL ACTIVATED BY MEANS OF OXALATE ESTERS PHARMACIA CORPORATION (US) 2004-09-02 WO claimed
EP-1131281-A2 DERIVATISATION OF SUPPORT SURFACES Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2001-09-12 EP claimed
WO-2000029373-A2 DERIVATISATION OF SUPPORT SURFACES Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) 2000-05-25 WO claimed
US-5446134-A Reacting bis(fluorosulfonyl)methane salt with cyanogen halide or pseudohalide CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 1995-08-29 US claimed
JP-1283550-A None JP disclosed
US-20250367188-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS ARDELYX, INC. (US) 2025-12-04 US disclosed
EP-0210545-A2 Phosphorous containing enzyme inhibitors MERCK & CO. INC. (US) 1987-02-04 EP disclosed
EP-0209897-A2 Peptide enzyme inhibitors MERCK & CO. INC. (US) 1987-01-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200388880-A1 SILICON-BASED ENERGY STORAGE DEVICES WITH ELECTROLYTE ADDITIVE COMPOUNDS SOST, CA1, DUOX2 MGLL 4206/4885PARL 3605/4885KMT2A 1999/4885
US-20100022415-A1 ACTIVE CARRIER, ITS PRODUCTION AND ITS USE SLC43A1, PAICS, PIGO MGLL 4194/4885PARL 4777/4885KMT2A 4205/4885
US-20250367188-A1 COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS SLC10A1, SLC10A2, FABP3 MGLL 1217/4885PARL 4076/4885KMT2A 3647/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.